HK Stock Market Move | GRAND PHARMA (00512) up over 5% again breaking through the peak. Institutions say the impact of centralized procurement of Lishuan is controllable and optimistic about the company's innovation value reshaping.

GRAND PHARMA (00512) rose more than 5% in midday trading, hitting a high of HK$9.18, setting a new record high for the listing. As of the time of writing, it is up 4.14% at HK$9.05 with a trading volume of HK$493 million. In terms of news, GRAND PHARMA has recently received multiple positive developments. The company's new drug STC3141 for the treatment of sepsis in the billion-dollar market has achieved success in Phase II clinical trials. This product is expected to break the long-standing lack of targeted drugs in the sepsis field and become the first groundbreaking therapy in critical care treatment. In addition, the company's innovative RDC product TLX591 has applied to join international multicenter Phase III clinical trials and has been accepted by the National Medical Products Administration. The Phase III clinical study of TLX591-CDx in China has completed the enrollment of all patients and plans to submit a new drug application for marketing in China within this year. The company's nuclear medicine global research and production base in Wenjiang, Chengdu, will officially start operation in June 2025. Huatai pointed out that market concerns about the company include the impact of the Lishuan collective procurement and the commercialization of innovative products. The firm believes that the company has developed into one of the most important market participants in China's nuclear medicine industry chain and is optimistic about the reshaping of GRAND PHARMA's innovative value with pipeline progress. Y90 will benefit from domestic commercial insurance reforms and hospital market expansion, and is expected to ramp up quickly between 2025 and 2027. The overall impact of the Lishuan collective procurement is manageable, and with accelerated business development and stable existing large products, the firm believes that the company's operating profit in 2025 can be maintained steadily.